We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Korean Practice Patterns for Screening PCA(Prostate Cancer) (RESPECT)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01371513
First Posted: June 10, 2011
Last Update Posted: May 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
May 12, 2011
June 10, 2011
May 22, 2017
May 2010
June 2011   (Final data collection date for primary outcome measure)
Number of subjects with prostate biopsy [ Time Frame: 1year ]
Same as current
Complete list of historical versions of study NCT01371513 on ClinicalTrials.gov Archive Site
Number of subjects with prostate cancer [ Time Frame: 1year ]
Same as current
Not Provided
Not Provided
 
Korean Practice Patterns for Screening PCA(Prostate Cancer)
Korean's Practice Patterns for Screening PCA(Prostate Cancer) According to PSA(Prostate-specific Antigen) Level
This is to investigate Korean urologist's practice patterns for screening prostate cancer according to PSA level.
This is to investigate Korean urologist's practice patterns for screening prostate cancer according to PSA level.
Observational
Observational Model: Other
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
Subjects with PSA more than 2.5ng/ml in 2008 from urology department of clinic and general hospital
  • Neoplasms, Prostate
  • Prostate Cancer
  • Benign Prostatic Hyperplasia
Other: continuous screening
practice patterns for screening prostate cancer
PSA level
more than 2.5ng/ml
Intervention: Other: continuous screening
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1
June 2011
June 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male with PSA more than 2.5ng/ml from 1 Jan 2008 to 31 Dec 2008

Exclusion Criteria:

  • Age less than 40 at PSA screening
  • History of drug use which can affect level of PSA within 6months before PSA screening
  • Subject who participate any other clinical trial
Sexes Eligible for Study: Male
40 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT01371513
113951
No
Not Provided
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
May 2017